Ariad Pharmaceuticals Inc fka ARIA

[jaybe]

The challenge for GIST is competing against a generic imatinib, and therefore having to run a head-to-head P3 trial to prove superior efficacy for 1st line use. This we will do, but could run approval and therefore appreciable sales into 2018.

Note the comparable (eligible for TKI in newly diagnosed) patient count for CML would be 13,300 WW. So GIST potential is 4 times the revenue of CML.